Philadelphia, PA · Founded 2023 · Privately Held (backing)
Developer of biological and small-molecule treatments designed for metabolic disease management. Alveus Therapeutics is based in Philadelphia, PA and was founded in 2023. It was valued at $275 million at its early-stage round in Feb 2026, the last priced event on record. It has raised $202 million across 1 recorded round; the latest was a $56.9 million later-stage round in Dec 2025.
PMV mark · valuation
$275.2M
Oct 2026
Priced at
its early-stage round
Feb 2026
Total raised
$202.0M
Last round
Later Stage VC
Dec 2025
Cap table — not yet on record
Alveus Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Alveus Therapeutics with a free account
·The complete investor list: 13 names
·Watch Alveus Therapeutics: the Monday email on marks, rounds and moves
Where does Alveus Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Alveus Therapeutics's 1 recorded funding rounds.
